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Background 1 Activation of the immune system, together with genomic alternation, including somatic hypermutation 2 and recombination, establishes innate and adaptive immunity in the immune system 1,2 . Both the 3 immunoglobulin (Ig) and the T cell receptor (TCR) loci contain many different V, D and J segments, 4 which are subject to a tightly regulated genomic rearrangement process -V(D)J recombinationduring 5 early lymphoid differentiation [3] [4] [5] . For a given TCR subtype, complementarity determining region 3 6 (CDR3) is generated by the V(D)J combination at this subtype locus, with the translated protein sequence 7 forming the center of the antigen binding site 6 , defining the affinity and specificity of the receptor for 8 individual peptide-MHC complexes. The CDR3 sequence of dominant clones in cancer patient may serve 9 as a signature to diagnose cancer or to classify tumor into subtypes. In addition, signatures could be 10 obtained at the time of disease diagnosis and then monitored on an ongoing basis, to assess the effects of 11 anticancer therapies or for early detection of recurrence 7,8 . 12
The importance of monitoring TCR in human health and disease has been increasingly recognized. 13
Recent studies showed that TCR repertoire has been found to affect a wide range of diseases, including 14 malignancy, autoimmune disorders and infectious diseases, and, given the broad involvement of the 15 immune system in almost all of human health and disease, this reach should be expected to expand greatly 16 9 . However, conventional methods to measure V(D)J recombination have several limitations to prevent 17 detailed characterization of immune repertoire. More recent approaches, such as multiparameter flow 18 cytometry, spectrotyping, or custom-designed real-time PCR assays, are slightly more quantitative and 19 offer higher resolution, but these methods are labor intensive and are unable to offer sequence-level 20 insights as to the exact V(D)J recombination patterns in patients. Solving this problem will enable the 21 wider application of monitoring immune repertoire in clinical settings. 22
With the development of massively parallel, single-molecule sequencing techniques, it has now become 23 feasible to assay V(D)J recombination by next-generation sequencing, as a means to exhaustively profile 24 the immune repertoire within human subjects. For example, the Roche 454 sequencers has been used to 25 measure and clinically monitor human lymphocyte clonality 10 , which takes advantage of 454's ability to 26 generate longer sequencing reads that potentially covers V(D)J recombination junction points. Another 27 similar study also used Roche 454 to study human T cell subsets 11 . Note that they separated T cell 28 subpopulations and focused on TCR loci only. However, other investigators have focused on Illumina 29
Genome Analyzer or HiSeq that generates only ~50 bp to ~100 bp reads. For example, a group has 30 developed a short reads assembly strategy to first assemble 50bp sequences and then sample the CDR3 1 diversity in human T lymphocytes from peripheral blood 12, 13 . The data analysis involved in such strategy 2 is much less straightforward, but the technology is more accessible and cost-effective in large scale 3 studies. Several additional TCR-Seq studies [13] [14] [15] [16] have been extensively reviewed recently. Some of the 4 commonalities include: (1) they almost always used T-cell DNA or RNA as the first starting material; (2) 5 most of the studies use multiplex PCR reactions to enrich the V(D)J recombinations for next-generation 6 sequencing; (3) large-scale T-cell repertoire analysis has been limited to interrogation of a single TCR 7 subunit per sequencing run, although functional antigen-engaging TCRs are heterodimeric proteins 8 comprising both an α and a ß chain. 9
In the current study, we explored the feasibility of using ligation-anchored PCR reaction, rather than 10 multiplex PCR reactions, for unbiased amplification of TCR-beta repertoire. The key aspect of our 11 approach is ligating a synthesized linker oligo sequence (/5Phos/NNN…NNN/3ddC/) to the 3'end of 12 single-stranded cDNA, thus it is applicable to extracted RNA samples. As shown below, the method 13 works with frozen whole blood. Additionally, similar to our previous study examining immunoglobulin 14 repertoire 17 , instead of relying on flow cytometry or magnetic beads to isolate T cells or B cell 15 populations from peripheral blood, we attempted to assay RNAs extracted from whole blood directly. 16
Finally, we evaluated sequencing data from the latest Illumina Hi-Seq2500 sequencer, which can generate 17 151bp single-end reads (~160 million reads per run), with a significantly shortened turnaround time (48 18 hours for Rapid Mode) compared to Illumina Hi-Seq2000 or Roche 454 sequencer. Despite the shorter 19 reads than 454 sequencer or Illumina MiSeq sequencer, 151bp read length is still long enough to map 20 V(D)J recombination sites, given appropriate primer design for PCR amplification. 21
To evaluate this approach, we did a pilot study on patients suffered from meningiomas, the most common 22 primary brain tumors in the United States 18,19 , and compared difference of the detected TRB repertoire 23 between patients with benign (grade I) and malignant (grade III) tumors. This tumor arises from the 24 membranous layers surrounding the central nervous system (CNS), and is not subject to blood-brain 25 barrier. Several previous studies have reported the presence of both humoral 20,21 and cellular 22,23 immune 26 responses in patients with meningiomas. Indeed, it has been proposed that frequent antibody response 27 against specific antigens in even benign meningioma can serve as diagnostic targets 20 . Therefore, in 28 addition to testing the technical feasibility, our pilot study has the added value of investigating whether 29 there is increased clonality with increased severity of cancer, and whether different patients may share 30 identical or similar CDR3 sequences in clonal T cells. 31 1 Results 2 Total RNA extraction and PCR amplification of TRB variable region 3 To explore all the actively transcribed immune receptor variable regions within whole blood in an 4 unbiased manner, we developed an integrative approach to extract total RNA from whole blood, followed 5 by a PCR protocol to capture the variable region (V-region) of specific immune receptor ( Figure 1A) . In 6 this scheme, after total RNA extraction from whole blood, we generate single-stranded cDNA from 7 reverse transcription of mRNA. After ligation of a synthesized linker oligo sequence to the 3'end of 8 single-stranded cDNA, PCR reaction was carried out using a primer pair (primers P-U and P-VDJ) to 9 target the linker sequence and the consensus starting sequence of immune receptor constant region (C-10 region), respectively. The P-VDJ primer was specifically designed such that it did not have high sequence 11
homology to any other region other than the TCR locus, and that it avoids any known SNPs. In our proof-12 of-concept study, total RNA extracted from whole blood of a healthy donor was used to test our 13 methodology on capturing TRB variable region ( Figure 1B) . For samples that were subject to both 14 reverse transcription (either oligo-dT or random primer mix) and linker ligation, PCR reaction resulted in 15 a predominant band with fragment size around 500 bp, roughly the size expected for TRB variable region. 16
For control samples without reverse transcription, this band was not visible. Additionally, controls 17 without linker ligation did not produce this specific band in DNA gel. Thus, the protocol developed in our 18 study should be able to capture transcribed TRB variants from whole blood directly, without separation of 19 T cells first. 20 21 TRB profiling using Illumina high-throughput sequencing 22 To further evaluate whether the developed protocol is applicable to profile TRB repertoire of clinical 23 samples, we tested the protocol on several blood samples from patients with malignant and benign 24 meningiomas (Supplementary Tables 1) . The fact that immune responses are present in patients with 25 meningiomas 20,21 suggests that immune receptors such as TCR may respond to this tumor type and serve 26 as a biomarker for diagnosis. We followed the same protocol to profile TRB V-region variants using 27 previously collected whole blood samples (stored at -80°C for more than one year) from two malignant 28 patients and two benign patients, respectively. Compared to controls without linker ligation, all four 29 reverse transcribed samples with ligation showed the expected predominant band (~500bp, Figure 2A) , 1 suggesting the robustness of this approach. The amplified fragments were further used for next-generation 2 sequencing library preparation. 3
Purified PCR amplicons were barcoded with Illumina TruSeq kit for high-throughput sequencing. The 4 latest Illumina HiSeq-2500 sequencer was used for sequencing, with load of ~30% PhiX for proper 5 matrixing and phasing into the lane. Collected sequencing data was filtered, and the selected reads were 6 mapped using IgBLAST (see Methods, Supplementary Tables 2&3). Of note, the majority of the reads 7 with either P-U or P-VDJ end tag contained TRB fragments (64% to 91% of the mapped TCRV-8 containing reads belong to TRB subtype). Other subtypes of TCR, such as TRA, TRD, TRG, only 9 accounted for a small portion of the TCRV-containing reads (Figure2B). Therefore, ligation-anchored 10 PCR approach is indeed capable of profiling TRB repertoire of clinical samples. 11 12 V-segment usage in benign and malignant patients. 13 We next compared the usage of different V-segments from TRB aligning reads (either end-tagged with P-14 U or P-VDJ primers) in patients with malignant and benign meningiomas. Interesting to note, two 15 malignant samples were grouped together in both P-U and P-VDJ tagged V-segment distribution heat 16 maps, suggesting overall similarity in V-segment usage (Figure 3A) . Although most of the V-segments 17 did not present consistent change of percentages in the total population between malignant and benign 18 samples ( Figure 3A) , one segment TRBV29-1 showed drastic increase in the malignant group (top 19 ranked gene from SAM analysis of MeV software suite, two-class unpaired, FDR<2%), revealing 20 expansion of this particular V-segment in whole blood of malignant patients. Consistent with this 21 discovery, when we further sorted out the translationally productive V(D)J reads within P-VDJ tagged 22 read pool (see Methods), we also noticed that TRBV29-1 level was elevated in malignant samples 23 ( Figure 3B) , with 5 to 7-fold increase of this population. In addition to TRBV29-1, another V-segment 24 TRBV15 also showed an increase in malignant phenotype. Therefore, the detected clonal expansion of 25 TRBV29-1 possibly reflects human immune response to malignant transformation of meningiomas. 26
Characterization of "immune signature" -CDR3
1 In addition to explore potential clonal expansion, we are also interested to evaluate our experimental 2 protocol in capturing the sequences of the CDR3 regions of TCR. From high-throughput sequencing data, 3
we deduced the unique DNA sequence logos of the FR3-CDR3 junction part (Figure 4A) with the last 20 4 nt of FR3 and the first 60 nt into CDR3 included, and evaluated if any signatures were recurrent features 5 that can separate malignant from benign patients. Initial observation at positions 54 and 56 (Figure 4A ) 6 revealed that the most frequent bases were C and G in the malignant samples; however, they switched to 7 base T in the benign samples. Positions 54 to 56 encode an amino acid that is in frame to TRB coding 8 sequence; in malignant samples, the encoded amino acid was Gln (Q), whereas in benign group, it 9 changed to Tyr (Y). We thus generated protein sequence logos of FR3-CDR3 junction (Figure 4B) for 10 further comparison. Of note, a conserved Cys (C) at the end of FR3 region (position 6) was separated 11 from a QXFGXGTRL motif in CDR3 by 11 and 10 amino acids in malignant and benign sample groups, 12
respectively. In a previous study 12 , two major CDR3 subsets with 42 nt and 45 nt were identified in a 13 pooled normal human leukocyte RNA sample. In our study, the protein sequence logos of meningioma 
Discussion and conclusions 1
In the current study, we presented an integrated approach by using single primer PCR together with next-2 generation sequencing to interrogate immune repertoire of TCR-beta. We have demonstrated the technical 3 feasibility to use this system to infer immune repertoire, using whole blood from four meningiomas 4 samples. By aligning reads to a sequence database of germline V-genes, D-genes and J-genes, the usage 5 of different V-gene segments was quantified. Interestingly, comparison between malignant and benign 6 groups revealed an increased usage of TRBV29-1 in malignant meningiomas. Analysis of CDR3 region 7 sequence logos revealed addition of 1 amino acid between FR3-CDR3 junction and a consensus motif in 8 malignant group. However, we caution that these observations were made on a small number of samples, 9 and they may not have any biological significance. Our purpose is to use these data to demonstrate the 10 technical feasibility of "single-primer" interrogation of immune repertoire, rather than determining what 11 differs between malignant and benign tumors. 12
There are several unique aspects of our protocol, compared to previous studies. First of all, total RNA is 13 extracted directly from frozen blood samples for profiling, thus the procedure can be easily adapted for There are several major limitations of our protocol as well. First, due to the need to add in 3'-adaptors to 19 the cDNA terminus for ligation-anchored PCR, our method relies on RNA samples, which are less readily 20 available and more vulnerable to degradation, compared to genomic DNA samples. However, in the 21 current study, we used frozen whole blood samples and still obtained satisfactory results, suggesting that 22 it is practically feasible to use this method in real-world clinical settings. Second, although Illumina Hi-23 Seq 2500 provided longer read length (151bp) than Illumina Hi-Seq 2000 (101bp) to cover immune 24 signature region CDR3, longer read length is still needed to cover the entire variable region of immune 25 genes. Thus the latest Illumina MiSeq with 250bp chemistry should be more suitable for profiling 26 immune repertoire. Third, our sequencing data showed higher sequencing depth of malignant sample 27 libraries (010_M, 221_M) compared to benign ones (Supplementary Table 2) . We acknowledge that 28 uneven mixing of the constructed libraries for sequencing could be the reason. To address the issue of 29 sequencing depth, we performed additional data analysis using the first 7 million sequencing reads of 30 010_M and 221_M data (Supplementary Figure, Supplementary Table 4&5 ). Of note, the results from the 7-million-read data were consistent with the conclusions from the whole sequencing data, indicating 1 that the sequencing depth in our study is deep enough. Fourth, we specifically designed primers to target 2 TCR-beta isoforms. Our sequencing data contained some other TCR isoforms as well, suggesting the 3 presence of some minor cross reactions. Our future studies may design specific primers for other types of 4 isoforms as well, to investigate whether it is feasible to interrogate all major TCR isoforms in the same 5 sequencing run. Finally, the sample size in our study is small, which prevents us to draw any statistically 6 significant conclusions on clonal expansion of TRB subtypes associated with malignant transformation of 7 meningiomas; however, the results from high-throughput sequencing data analysis do support validity of 8 the developed integrated approach. 9
In conclusion, we have developed a ligation-anchored PCR approach to interrogate immune repertoire, 10 and demonstrated its technical feasibility and effectiveness in capturing the TCR-beta landscapes. 
Linker ligation and PCR amplification of TRB variants
1 For each reverse transcribed product, AMPure XP magnetic beads (Beckman Coulter, Danvers, MA) was 2 added to the mixture, followed by 80% ethanol wash to remove primers introduced in reverse 3 transcription step. Each sample was eluted in 30µL EB buffer (QIAGEN, Valencia, CA) with 1µL RNase 4 H (10U/µL, Epicentre, Madison, WI) and 2µL RNase A (5µg/µL, Epicentre, Madison, WI) added to 5 digest RNA templates for 1 hour at 37C, followed by a heat-inactivation step for 5 min. at 95°C. 6
Ligation of the linker primer to RNase-treated cDNA sample (ssDNA) was carried out in a total volume 7 of 60L using T4 RNA ligation kit (Promega, Madison, WI) following vendor recommended protocol. 8
The linker primer was synthesized (Integrated DNA Technologies, San Diego, CA) based on the sequence 9 and modification in a previous study 25 . The mixture was incubated overnight at room temperature. For 10 control reaction, ddH 2 O instead of T4 RNA ligase (Promega, Madison, WI) was added. 11
After overnight incubation, the ligation product was incubated with AMPure XP beads for magnetic 12 purification. Each sample was eluted in 20µL ddH 2 O. PCR reaction was performed using HotStart PCR 13 reagent kit (EMD Chemicals, Billerica, MA) with 2µL of ligated ssDNA as PCR template. In a reaction 14 mixture without primer loaded, a universal primer targeting the linker (GCG GCC GCT TAT TAA CCC) 15 was first added for 2 nd strand synthesis at 95°C for 2.5 min., 70°C for 5min. and 4°C forever. Then 16 another primer targeting the consensus sequence of TRB constant region (GAC CTC GGG TGG GAA 17 CAC) was added for 40 cycles of PCR reaction with annealing at 65°C and extension at 70°C. 18 
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NGS library preparation and sequencing
Analysis of sequencing data
1 For the raw FASTQ data collected from high-throughput sequencing, sequencing quality analysis was 2 first performed using FASTQC 26 to ensure the mean values of sequence quality (Phred Score) for each 3 base is greater than 32. Then a custom PERL script was used to select the reads with the starting 4 sequences containing either P-U (with additional 5 bp extended to the ligation site) or P-VDJ primer 5 sequence. Unlike genome or exome sequencing, the nature of sequencing data from immune gene 6 variable regions requires 1) mapping against a sequence database containing V-gene, D-gene and J-gene 7 segments; and 2) aligning the V(D)J junctions formed. For mapping of the sequenced reads, recently 8 released IgBLAST 27 was employed to identify reads that can be mapped to germline V, V-D, V-J, or V-9 D-J segments. The default parameters were used for mapping. Due to lack of a standalone version of 10 IgBLAST for TCR gene analysis, the sequencing data (reformatted to FASTA files) were split into small 11 batches and uploaded to the IgBLAST web server for mapping. Hierarchical clustering analysis was 12 carried out using MEV, which is a component of the TM4 suite of microarray analysis tools 28 . Sequence 13 logo graphs were generated using standalone version of WebLogo (weblogo.berkeley.edu) 29 . Circos 14 maps were plotted using Circos Table Viewer web 
